脉血康胶囊联合瑞舒伐他汀对冠脉临界病变患者冠脉病变程度的影响

目的研究脉血康胶囊联合瑞舒伐他汀对冠脉临界病变患者钙库操纵性钙通道蛋白(SOCC)基质交联分子1(STIM1)、钙释放激活钙通道蛋白Orai1及瞬时受体电位通道1(TRPC1)蛋白水平和冠脉病变严重程度的影响。方法将2015年1月—2016年12月北京安贞医院经定量冠脉造影检查确诊冠脉临界病变(BCL)住院患者160例设为临界病变组(BCL组),150例无冠脉病变的受试者为对照组(简称CTR组)。BCL组随机分为常规治疗组(简称RTT组,80例)和联合治疗组(简称CBT组,80例)。RTT组给予生活方式改善、阿司匹林、AECI、β受体阻滞剂及瑞舒伐他汀10 mg等药物。CBT组在常规药物治疗基础上,每日加用瑞舒伐他汀15 mg和脉血康胶囊3.0 g,连续治疗12个月。检测血小板STIM1、Orai1、TRPC1、高敏C-反应蛋白(hs-CRP)水平及TC、LDL-C、HDL-C、TG浓度。评价BCL组平均狭窄程度(MPS)。结果BCL组130例受试者复查冠脉造影。与本组治疗前比较,治疗后CBT组和RTT组血小板STIM1、Orai1、TRPC1水平均降低(P<0.05);CBT组冠脉临界病变的MPS明显减低(59.74±9.72vs.38.92±13.84,P<0.05),RTT组MPS有所下降(58.96±8.67vs.55.43±10.03),但差异无统计学意义(P>0.05)。与RTT组比较,治疗后CBT组血小板STIM1、Orai1、TRPC1、TC、LDL-C、TG、和hs-CRP明显降低(P<0.05,P<0.01),且CBT组MPS差值大于RTT组(P<0.01)。结论脉血康胶囊3.0 g和瑞舒伐他汀15 mg每日联合应用可降低SOCC水平,其可能是冠脉临界病变治疗的优化选择。

Effect of Maixuekang Capsule and Rosuvastatin on Severity of Coronary Lesion in Patients with Borderline Coronary Lesion

Objective To study the changes of store operated calcium channel(SOCC)stromal interacting molecule 1(STIM1),Orai1,transient receptor potential canonical 1(TRPC1)levels,and evaluate the effects of the combination of rosuvastatin and Maixuekang Capsule on them and severity of coronary lesion in patients with borderline coronary lesion(BCL).Methods Totally 160 consecutive patients with BCL assessed by quantitative coronary angiography from January 2015 to December 2016 were enrolled into BCL group,and 150 subjects without coronary lesion as control group(controls,CTR).And in the meantime,the subjects in BCL were randomized into routine treatment(RTT,80 cases)group with lifestyle amelioration,aspirin,angiotensin converting enzyme inhibitors,βblocking agent,and rosuvastatin 10 mg daily,and combined treatment(CBT,80 cases)group with rosuvastatin 15 mg plus Maixuekang Capsule 3.0 g daily besides routine medication,treated for 12 months continuously.Blood platelet STIM1,Orai1,TRPC1 levels,high-sensitive C-reactive protein(hs-CRP),total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C)and triglycerides(TG)were determined.And mean percent stenosis(MPS)was evaluated.Results One hundred and thirty subjects in BCL rechecked coronary angiography.Compared with before treatment in the same group,STIM1,Orai1,TRPC1 level were significantly decreased in RTT and CBT(P<0.05).Moreover,MPS of BCL was significantly low er in CBT and slightly decreased in RTT before and after 12-month treatment(59.74±9.72vs.38.92±13.84,P<0.05;58.96±8.67vs.55.43±10.03,P>0.05).Compared with RTT,STIM1,Orai1,TRPC1 level,TC,LDL-C,TG and hs-CRP were significantly decreased in CBT after 12-month treatment(P<0.05,P<0.01),and the MPS difference in CBT was more than that in RTT(P<0.01).Conclusion The combination treatment of Maixuekang Capsule 3.0 g plus rosuvastatin 15 mg daily decreased SOCC level,and could be the optimum treatment of choice.